Ceritinib (Zykadia®)

Assessment Status Rapid Review complete
Drug Ceritinib
Brand Zykadia®
Indication For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
Assessment Process
Rapid review commissioned 29/05/2015
Rapid review completed 22/07/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations.